September 14, 2009 - ZaBeCor Pharmaceuticals announced the initiation of a Phase II clinical trial for its asthma drug candidate ExcellairTM, following the successful results of the Company’s Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.“The advancement of ExcellairTM into a Phase II clinical trial for asthma is a significant milestone for our company... ZaBeCor Pharmaceuticals' Press Release -
